Biogen’s (BIIB) Buy Rating Reiterated at Truist Financial

Truist Financial restated their buy rating on shares of Biogen (NASDAQ:BIIB) in a research note released on Thursday,Benzinga reports. The brokerage currently has a $260.00 target price on the biotechnology company’s stock, up from their prior target price of $235.00.

Other equities research analysts also recently issued reports about the company. Robert W. Baird raised their target price on Biogen from $250.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday. HSBC upped their price target on Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Morgan Stanley upped their price target on Biogen from $222.00 to $231.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Guggenheim increased their price objective on shares of Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Finally, TD Cowen lifted their price objective on shares of Biogen from $225.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $251.00.

Biogen Trading Up 1.6%

NASDAQ:BIIB opened at $253.62 on Thursday. The business’s 50-day moving average is $227.08 and its two-hundred day moving average is $201.04. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.26. Biogen has a 12 month low of $146.52 and a 12 month high of $258.78. The firm has a market capitalization of $37.49 billion, a PE ratio of 108.38, a price-to-earnings-growth ratio of 2.97 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. During the same quarter in the previous year, the firm posted $4.81 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. Research analysts predict that Biogen will post 12.44 earnings per share for the current fiscal year.

Institutional Trading of Biogen

Hedge funds have recently made changes to their positions in the stock. Bell Investment Advisors Inc acquired a new stake in Biogen during the second quarter valued at approximately $27,000. Align Financial LLC grew its position in shares of Biogen by 339.3% in the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 95 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new position in shares of Biogen in the 3rd quarter worth approximately $29,000. Canton Hathaway LLC bought a new stake in shares of Biogen in the 3rd quarter valued at approximately $31,000. Finally, Ashurst Perkins Coie Trust Co increased its holdings in shares of Biogen by 92.2% in the 3rd quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 83 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.